Bone imaging plays a pivotal role in the diagnosis, treatment planning and follow‐up of patients with cancer metastasis. Advances in hybrid imaging modalities, particularly single-photon ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial. Phase ...

WHIPPANY, N.J., May 28, 2025--ASCO 2025: XOFIGO® Combination Data Showcases Clinical Benefits in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases ...

WHIPPANY, N.J., May 28, 2025--(BUSINESS WIRE)--New data from two clinical trials evaluating XOFIGO ® (radium-223 dichloride) in patients with metastatic castration-resistant prostate cancer (mCRPC) ...

Zoledronic acid has several advantages over other bisphosphonates. In addition to having broader clinical utility, zoledronic acid can safely be infused over 15 minutes rather than the 2 hours ...

Metastatic bone cancer occurs when other cancers spread to the bone. Having any cancer is a risk factor for metastatic bone cancer. Treatment. Treatment depends on the type of cancer, ...

Bones At the time of non-small cell lung cancer (NSCLC) diagnosis, the cancer has already spread to the bone in 20 to 30 percent of people, and 35 to 60 percent will develop bone metastasis in the ...

Certain medications used in the treatment of bone conditions, particularly when combined with corticosteroids, may significantly increase the risk of a rare but serious jaw disease. This finding ...